id: NEW:chloroquine_treatment_covid19_to_all_cause_mortality_rate
name: Chloroquine Treatment for COVID-19 â†’ All-Cause Mortality Rate
from_node:
  node_id: NEW:chloroquine_treatment_covid19
  node_name: Chloroquine Treatment for COVID-19
to_node:
  node_id: all_cause_mortality_rate
  node_name: All-Cause Mortality Rate
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Chloroquine administered to COVID-19 patients based on theoretical antiviral properties'
- 'Step 2: Drug has known cardiac toxicity profile similar to hydroxychloroquine'
- 'Step 3: No demonstrated therapeutic benefit against SARS-CoV-2 infection in clinical trials'
- 'Step 4: Potential for adverse events without offsetting clinical improvement'
- 'Step 5: No mortality benefit observed, with wide confidence intervals due to limited data'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: C. Axfors et al. 2021. "Mortality outcomes with hydroxychloroquine and chloroquine
    in COVID-19 from an international collaborative meta-analysis of randomized trials." https://doi.org/10.1038/s41467-021-22446-z
  supporting_citations:
  - RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19.
    N Engl J Med.
  - WHO SOLIDARITY Trial Consortium. Repurposed antiviral drugs for Covid-19. N Engl J Med.
  - Additional citations require full-text access for identification of specific chloroquine RCTs
  doi: 10.1038/s41467-021-22446-z
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Meta-analysis of 4 randomized controlled trials (307 patients) found no mortality benefit
  from chloroquine treatment for COVID-19 (OR 1.77, 95% CI 0.15-21.13). The extremely wide confidence
  intervals reflect the small evidence base and preclude definitive conclusions, though the point estimate
  suggests potential harm.
quantitative_effects:
  effect_size:
    value: 1.77
    type: odds_ratio
    ci_lower: 0.15
    ci_upper: 21.13
  sample_size: 307
  heterogeneity_i_squared: 0.0
moderators:
- name: sample_size
  direction: weakens
  strength: strong
  description: Very limited sample size (307 patients) results in imprecise estimates with extremely wide
    confidence intervals
structural_competency:
  equity_implications: The limited evidence base for chloroquine reflects structural challenges in pandemic
    research coordination. Different countries pursued different antimalarial drugs based on local availability
    and regulatory environments. This fragmentation of research efforts across similar but not identical
    interventions reduced statistical power to detect effects. The finding highlights how global health
    infrastructure and research coordination systems affect the quality of evidence available for clinical
    decision-making.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.880304'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
